Hybio Pharmaceutical (SHE:300199) will sell glucagon-like peptide (GLP-1) raw materials to an unnamed customer for 180 million yuan, according to a Friday disclosure to the Shenzhen bourse.
GLP-1 helps regulate blood sugar and appetite and is used in slimming products.
The amount is equivalent to about 31% of the entire audited revenue of the listed company in 2024, according to the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.